International Biotechnology Trust (IBT)
market vs.
industry GROWTH & VALUE
| Trailing 12m | ||||
| PE Ratio (ttm) | 3.65 |
|
|
|
| PEG Ratio (ttm) |
|
|
||
| EPS Growth (ttm) | % |
|
|
|
| Dividend Yield (ttm) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 1.07 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry QUALITY
| Year End 31st Aug | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013E | 2014E | CAGR / Avg | |
| Revenue | £m | |||||||||
| Operating Profit | £m | |||||||||
| Net Profit | £m | |||||||||
| EPS Reported | p | |||||||||
| EPS Normalised | p | |||||||||
| EPS Growth | % | |||||||||
| PE Ratio | x | |||||||||
| PEG | x | |||||||||
| Profitability | ||||||||||
| Operating Margin | % | |||||||||
| ROA | % | |||||||||
| ROCE | % | |||||||||
| ROE | % | |||||||||
| Cashflow | ||||||||||
| Op. Cashflow ps | p | |||||||||
| Capex ps | p | |||||||||
| Free Cashflow ps | p | |||||||||
| Dividends | ||||||||||
| Dividend ps | p | |||||||||
| Dividend Growth | % | |||||||||
| Dividend Yield | % | |||||||||
| Dividend Cover | x | |||||||||
| Balance Sheet | ||||||||||
| Cash etc | £m | |||||||||
| Working Capital | £m | |||||||||
| Net Fixed Assets | £m | |||||||||
| Net Debt | £m | |||||||||
| Book Value | £m | |||||||||
| Average Shares | m | |||||||||
| Book Value ps | p | +9.9% | ||||||||
FINANCIAL BRIEF: For the fiscal year ended 31 August 2012, International Biotechnology Trust Plc revenues increased from L7.3M to L40.1M. Net income increased from L4.6M to L38M. Revenues reflect Deposit Interest increase from L0K to L260K, Interest on Debt Securities increase from L2K to L108K. Net income benefited from Director's Fees decrease of 11% to L163K (expense). more »
| Leverage (ttm) | Total | Ex Intang | |||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % | ||||
| Liquidity (ttm) | ||
| Current Ratio | ||
| Quick Ratio | ||
| Interest Cover | ||
| Efficiency (ttm) | ||
| Asset Turnover | ||
| Rec's Turnover | ||
| Stock Turnover | ||
market vs.
industry RECENT HISTORY
| Latest interim period (ended 31st Aug '12) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Average Annualised | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
BROKER CONSENSUS & FORECAST TREND
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: | 0 | 0 | 1 | 0 | 0 |
International Biotechnology Trust plc is an investment company. The investment objective of the Company is to achieve long-term capital growth by investing primarily in biotechnology and other life sciences companies. The majority of the Company’s assets are invested in smaller and mid capitalization quoted companies, with a minority in larger capitalization quoted companies. The Investment Manager seeks to invest up to 30% of the Company’s assets in unquoted companies, while allowing an exposure of up to 40% in unquoted companies after allowing for valuation write-ups and further follow-on investments. As of August 31, 2012, the Company held investments in 70 companies: 45 quoted and 25 unquoted companies. During the fiscal year ended March 31, 2012, the Company investments included Amgen, Celgene, Alexion Pharmaceuticals, Aptiv Solutions, Insulet, Pharmaxis and Gilead Sciences. The Company’s investment manager is SV Life Sciences Managers LLP.
No Management Information.
No. of Employees: 0 No. of Shareholders: n/a
| Last Annual | August 31st, 2012 |
| Last Interim | August 31st, 2012 |
| Shares in Issue | 55,457,663 |
| Free Float | 45.0m (81.1%) |
| Sector | Financials |
| Industry | Collective Investments |
| Index | |
| Exchange |
London Stock Exchange (Full) |
| Eligible for | an ISA? a SIPP? |
| Address | , LONDON, EC2R 6PA, United Kingdom |
| Web | http://www.ibtplc.com |
| Phone | +44 20 74103878 |
| Contact | () |
| Registrar | Equiniti Limited |
| Auditors | PricewaterhouseCoopers LLP |
